COMPANY PROFILE

NEX-I

Explore full profile

ONCOKINE cancer immunotherapy platform

Seoul, South KoreaFounded 2021Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Total funding $50–100M Disclosed equity funding

Unlock exact values

About NEX-I

NEX-I is a biotech company developing next-generation cancer immunotherapy. Its ONCOKINE platform is designed to identify and target cancer cells that resist conventional treatments, with a focus on refractory oncology indications.

The company works toward proprietary cancer therapies built on that platform, with potential paths through partnerships, licensing, and commercialization with healthcare and pharmaceutical collaborators. Customers and partners include healthcare providers, research institutions, and pharmaceutical companies interested in refractory-cancer approaches.

Business model centers on developing and advancing oncology therapeutics via the ONCOKINE platform.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Seoul, South Korea
Open positions: None listed
Dealroom signal: 22.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Aug 2025	$73M	$292M	Undisclosed	↗
SERIES AOther financing	Oct 2022	$18M	$74M	WONIK Investment Partners · Schmidt · GC Pharma · Atinum Investment	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

NEX-I website traffic

Latest recorded traffic for NEX-I is 3.8K monthly website visits, up 46.2% over the last three months.

Latest monthly visits3.8K 3-month web change+46.2%

Monthly website visitsMay 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AOAobaixinR&D and production of nucleotide raw materials	China	Operational	5	—	—
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational